Peter Mwitari
Kenya Medical Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Mwitari.
PLOS ONE | 2013
Peter Mwitari; Peter Amwoga Ayeka; Joyce Ondicho; Esther N. Matu; Christine Bii
Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus are used traditionally in Kenya for treatment of microbial infections and cancer. Information on their use is available, but scientific data on their bioactivity, safety and mechanisms of action is still scanty. A study was conducted on the effect of organic extracts of these plants on both bacterial and fungal strains, and their mechanisms of action. Extracts were evaluated through the disc diffusion assay. Bacteria and yeast test strains were cultured on Mueller-Hinton agar and on Sabouraud dextrose agar for the filamentous fungi. A 0.5 McFarland standard suspension was prepared. Sterile paper discs 6 mm in diameter impregnated with 10 µl of the test extract (100 mg/ml) were aseptically placed onto the surface of the inoculated media. Chloramphenicol (30 µg) and fluconazole (25 µg) were used as standards. Discs impregnated with dissolution medium were used as controls. Activity of the extracts was expressed according to zone of inhibition diameter. MIC was determined at 0.78–100 mg/ml. Safety studies were carried using Cell Counting Kit 8 cell proliferation assay protocol. To evaluate extracts mechanisms of action, IEC-6 cells and RT-PCR technique was employed in vitro to evaluate Interleukin 7 cytokine. Investigated plants extracts have both bactericidal and fungicidal activity. W. ugandensis is cytotoxic at IC50<50 µg/ml with MIC values of less than 0.78 mg/ml. Prunus africana shuts down expression of IL 7 mRNA at 50 µg/ml. W. somnifera has the best antimicrobial (1.5625 mg/ml), immunopotentiation (2 times IL 7 mRNA expression) and safety level (IC50>200 µg/ml). Fractions from W. ugandensis and W. somnifera too demonstrated antimicrobial activity. Mechanisms of action can largely be attributed to cytotoxicity, Gene silencing and immunopotentiation. Use of medicinal plants in traditional medicine has been justified and possible mechanisms of action demonstrated. Studies to isolate and characterize the bioactive constituents continue.
PLOS ONE | 2018
Noah Machuki Onchieku; Reagan Moseti Mogire; Loise Ndung'u; Peter Mwitari; Francis Kimani; Damaris Matoke-Muhia; Daniel Kiboi; Gabriel Magoma
Retroviral protease inhibitors (RPIs) such as lopinavir (LP) and saquinavir (SQ) are active against Plasmodium parasites. However, the exact molecular target(s) for these RPIs in the Plasmodium parasites remains poorly understood. We hypothesised that LP and SQ suppress parasite growth through inhibition of aspartyl proteases. Using reverse genetics approach, we embarked on separately generating knockout (KO) parasite lines lacking Plasmepsin 4 (PM4), PM7, PM8, or DNA damage-inducible protein 1 (Ddi1) in the rodent malaria parasite Plasmodium berghei ANKA. We then tested the suppressive profiles of the LP/Ritonavir (LP/RT) and SQ/RT as well as antimalarials; Amodiaquine (AQ) and Piperaquine (PQ) against the KO parasites in the standard 4-day suppressive test. The Ddi1 gene proved refractory to deletion suggesting that the gene is essential for the growth of the asexual blood stage parasites. Our results revealed that deletion of PM4 significantly reduces normal parasite growth rate phenotype (P = 0.003). Unlike PM4_KO parasites which were less susceptible to LP and SQ (P = 0.036, P = 0.030), the suppressive profiles for PM7_KO and PM8_KO parasites were comparable to those for the WT parasites. This finding suggests a potential role of PM4 in the LP and SQ action. On further analysis, modelling and molecular docking studies revealed that both LP and SQ displayed high binding affinities (-6.3 kcal/mol to -10.3 kcal/mol) towards the Plasmodium aspartyl proteases. We concluded that PM4 plays a vital role in assuring asexual stage parasite fitness and might be mediating LP and SQ action. The essential nature of the Ddi1 gene warrants further studies to evaluate its role in the parasite asexual blood stage growth as well as a possible target for the RPIs.
PLOS Neglected Tropical Diseases | 2017
Ruth Monyenye Nyangacha; David Odongo; Florence A. Oyieke; Missiani Ochwoto; Richard Korir; Ronald Kiprotich Ngetich; Gladys Nginya; Olipher Makwaga; Christine Bii; Peter Mwitari; Festus Tolo
Tungiasis or jigger infestation is a parasitic disease caused by the female sand flea Tunga penetrans. Secondary infection of the lesions caused by this flea is common in endemic communities. This study sought to shed light on the bacterial pathogens causing secondary infections in tungiasis lesions and their susceptibility profiles to commonly prescribed antibiotics. Participants were recruited with the help of Community Health Workers. Swabs were taken from lesions which showed signs of secondary infection. Identification of suspected bacteria colonies was done by colony morphology, Gram staining, and biochemical tests. The Kirby Bauer disc diffusion test was used to determine the drug susceptibility profiles. Out of 37 participants, from whom swabs were collected, specimen were positive in 29 and 8 had no growth. From these, 10 different strains of bacteria were isolated. Two were Gram positive bacteria and they were, Staphylococcus epidermidis (38.3%) and Staphylococcus aureus (21.3%). Eight were Gram negative namely Enterobacter cloacae (8.5%), Proteus species (8.5%), Klebsiellla species (6.4%), Aeromonas sobria (4.3%), Citrobacter species (4.3%), Proteus mirabillis(4.3%), Enterobacter amnigenus (2.1%) and Klebsiella pneumoniae (2.1%). The methicillin resistant S. aureus (MRSA) isolated were also resistant to clindamycin, kanamycin, erythromycin, nalidixic acid, trimethorprim sulfamethoxazole and tetracycline. All the Gram negative and Gram positive bacteria isolates were sensitive to gentamicin and norfloxacin drugs. Results from this study confirms the presence of resistant bacteria in tungiasis lesions hence highlighting the significance of secondary infection of the lesions in endemic communties. This therefore suggests that antimicrobial susceptibility testing may be considered to guide in identification of appropriate antibiotics and treatment therapy among tungiasis patients.
European journal of medicinal plants | 2016
Simon Alem; Festus Tolo; Nicholas Adipo; Peter Mwitari; Ngetich Japheth; Anselimo Makokha
Objective: To evaluate in vitro anti-Herpes simplex type 1 activity of methanol and aqueous crude extracts of pyrethrum (Chrysanthemum cinerariaefolium) plant grown in Kenya. Methods: Cytotoxic effect of methanol and aqueous extracts was determined on vero cells (African green monkey kidney cells) by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-DiphenylTetrazolium Bromide) reduction colorimetric assay. Antiviral effect of pyrethrum extracts was evaluated; before (posttreatment infection) virus infection to the cells and after (pre-treatment infection) virus infection to cells. Original Research Article Alem et al.; EJMP, 17(2): xxx-xxx, 2016; Article no.EJMP.28967 2 Results: Methanol extract exhibited higher cytotoxicity of CC50 = 42.23 ± 0.320 μg/ml compared to aqueous extract of CC50 = 249 ± 8.4 μg/ml. Methanol extract exhibited a higher anti HSV-1 potency of IC50 = 1.69 μg/ml (TI = 24.99) than the aqueous extract of IC50 = 38.13 μg/ml (TI = 6.53) in the post-treatment infection evaluations. This might be due to its effect on cellular receptors preventing virus entry, while the aqueous extract exhibited higher virus inhibitory potency in the pre-treatment infection, of IC50 = 23.21 μg/ml (TI=10.73) compared to the methanol extract of IC50 = 11.18 μg/ml (TI =3.78), this effect could be due to its effect on some stage during HSV virus replication process. Conclusions: Crude methanol and aqueous extracts from Kenyan grown pyrethrum exhibited inhibition potency against HSV-1 in vitro on Vero cells.
Journal of Ethnopharmacology | 2008
James W. Gathirwa; G.M. Rukunga; E.N.M. Njagi; Sabah A. Omar; Peter Mwitari; Anastasia N. Guantai; Festus Tolo; Cecilia W. Kimani; C.N. Muthaura; P.G. Kirira; T.N. Ndunda; G. Amalemba; G.M. Mungai; Isaiah O. Ndiege
Journal of Ethnopharmacology | 2007
C.N. Muthaura; G.M. Rukunga; S.C. Chhabra; Sabah A. Omar; Anastasia N. Guantai; J.W. Gathirwa; Festus Tolo; Peter Mwitari; Lucia Keter; Peter G. Kirira; Cecilia W. Kimani; G.M. Mungai; E.N.M. Njagi
Phytotherapy Research | 2007
C.N. Muthaura; G.M. Rukunga; S.C. Chhabra; Sabah A. Omar; Anastasia N. Guantai; J.W. Gathirwa; Festus Tolo; Peter Mwitari; Lucia Keter; Peter G. Kirira; Cecilia W. Kimani; G.M. Mungai; E.N.M. Njagi
Journal of Natural Medicines | 2007
James W. Gathirwa; G.M. Rukunga; E.N.M. Njagi; Sabah A. Omar; Anastasia N. Guantai; C.N. Muthaura; Peter Mwitari; Cecilia W. Kimani; Peter G. Kirira; Festus Tolo; Teresia N. Ndunda; Isaiah O. Ndiege
BMC Complementary and Alternative Medicine | 2016
Peter Amwoga Ayeka; Yuhong Bian; Peter Mwitari; Xiaoqian Chu; Yanjun Zhang; Rosette Uzayisenga; Elick O. Otachi
Journal of Cancer Science & Therapy | 2016
Chengo Jk; Adipo N; Kiboi Dm; Lusweti Jm; Mwatha J; Peter Mwitari; Ngule Cm; Njagi Sm